Saturday, 17 October 2026European Markets

HDF Stock Bearish By 9% So Far Today

Loading stream...

(vianews) - shares of hdf (cac 40: hdf.pa) fell 9.2% to €13.62 at 14:51 est on wednesday, after five successive sessions in a row of losses. cac 40 is jumping 0.01% to €7,534.41, following the last session's upward trend. this seems, so far, a somewhat up trend exchanging session today.

about hdf

hydrogène de france société anonyme develops and operates as independent power producer in france and internationally. it operates two hydrogen power plants; and manufactures and sells high power fuel cells. the company was incorporated in 2012 and is based in lormont, france.

earnings per share

as for profitability, hdf has a trailing twelve months eps of €-0.18.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, hdf's stock is considered to be overbought (>=80).

volatility

hdf's last week, last month's, and last quarter's current intraday variation average was a negative 2.67%, a negative 1.69%, and a positive 1.44%.

hdf's highest amplitude of average volatility was 2.67% (last week), 1.88% (last month), and 1.44% (last quarter).

volume

today's last reported volume for hdf is 10033 which is 253.52% above its average volume of 2838.

more news about hdf (hdf.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com